Hebei Jianxin Chemical Co., Ltd. (300107.SZ) Bundle
Who's buying into Hebei Jianxin Chemical Co., Ltd. (300107.SZ) and why should investors care? With insiders controlling a commanding 51% of the company and the largest individual holder, Shouchen Zhu, owning 38%, Hebei Jianxin's ownership is highly concentrated and governance leans toward major stakeholders; the top five shareholders together hold 51%, while the CEO, Xuewei Chen, personally retains 1.2%, and the second- and third-largest holders own 6.4% and 3.6% respectively-factors that shape strategic decisions with limited institutional oversight. The company's specialty-chemical niche-producing intermediates for dyes, pharmaceuticals and aviation materials-along with patents and exports to Europe, the United States, Japan and Korea, attracts investors seeking exposure to international specialty-chemical supply chains; the market has priced some of that confidence in, with a market capitalization of about CNY 5.6 billion as of February 16, 2025 and a +7.1% stock gain ahead of that valuation, while a low beta of 0.505 marks the stock as less volatile than the broader market-yet the investment case is complicated by a 25.35% year-over-year revenue decline in the trailing twelve months to June 30, 2025, raising immediate questions about growth sustainability that we unpack below.
Hebei Jianxin Chemical Co., Ltd. (300107.SZ) - Who Invests in Hebei Jianxin Chemical Co., Ltd. and Why?
- Insider ownership: insiders control a significant 51% stake, signaling strong internal confidence and alignment with shareholder value creation.
- Largest individual shareholder: Shouchen Zhu holds 38% of shares, giving substantial personal exposure and influence over strategy and governance.
- Institutional presence: minimal - the company is not widely held by professional investors, indicating limited institutional interest or a tightly held free float.
| Holder Category | Representative | Ownership (%) | Implication |
|---|---|---|---|
| Insiders / Management | Collective (incl. Shouchen Zhu) | 51 | High alignment with long-term strategy; lower free float |
| Largest Individual | Shouchen Zhu | 38 | Concentrated influence; potential for decisive strategic direction |
| Institutional Investors | Mutual funds / Asset managers | Minimal | Limited institutional liquidity and analyst coverage |
| Retail / Other | Public minority holders | ~49 (net of insiders) | Remaining tradable float; price sensitivity to retail flows |
- Sector appeal: investors seeking exposure to specialty chemical intermediates (dyes, pharmaceuticals, aviation materials) are drawn to Hebei Jianxin's niche product mix and margin profiles.
- Export footprint: active exports to Europe, the United States, Japan, and Korea attract investors focused on companies with international revenue diversification and access to higher-margin overseas markets.
- Innovation and R&D: multiple patents and ongoing product development make the company appealing to investors prioritizing technological moat and product differentiation in specialty chemicals.
- Governance/control considerations: concentrated insider ownership reassures some long-term, strategic investors while deterring others who prefer broader institutional governance oversight.
Hebei Jianxin Chemical Co., Ltd. (300107.SZ) Institutional Ownership and Major Shareholders of Hebei Jianxin Chemical Co., Ltd. (300107.SZ)
As of February 16, 2025, ownership of Hebei Jianxin Chemical Co., Ltd. (300107.SZ) is highly concentrated among a small group of shareholders. The top five shareholders together control 51% of the company, with the single largest holder owning a dominant share. Insider ownership is meaningful through senior management, while institutional participation remains minimal compared with industry norms. For context on the company's broader financials and health, see Breaking Down Hebei Jianxin Chemical Co., Ltd. Financial Health: Key Insights for Investors.
- Top 5 shareholders control: 51% of total shares outstanding (as of 2025-02-16).
- Largest shareholder: Shouchen Zhu - 38.0%.
- Second largest: 6.4%.
- Third largest: 3.6%.
- Insider (CEO Xuewei Chen) direct holding: 1.2%.
- Institutional ownership: minimal - limited professional investor stakes reported.
| Rank | Shareholder | Ownership (%) | Notes |
|---|---|---|---|
| 1 | Shouchen Zhu | 38.0 | Controlling individual shareholder |
| 2 | Second-largest shareholder | 6.4 | Institution/individual (reported stake) |
| 3 | Third-largest shareholder | 3.6 | Institution/individual (reported stake) |
| 4 | Fourth-largest shareholder | 2.0 | Part of top-5 aggregate |
| 5 | Fifth-largest shareholder | 1.0 | Part of top-5 aggregate |
| - | CEO (Xuewei Chen) - insider | 1.2 | Direct holding by chief executive |
- Governance implications: concentrated control (38% by a single shareholder) can drive strategic decisions and board composition toward majority-owner priorities.
- Minority investor risks: with limited institutional oversight, minority shareholders may face reduced monitoring and lower influence on corporate policy.
- Market signaling: atypically low institutional ownership versus industry peers suggests either perceived governance risk, low liquidity, limited coverage, or undervaluation depending on investor view.
Hebei Jianxin Chemical Co., Ltd. (300107.SZ) Key Investors and Their Impact on Hebei Jianxin Chemical Co., Ltd. (300107.SZ)
Major shareholders and insiders control a material portion of Hebei Jianxin Chemical Co., Ltd. (300107.SZ), shaping governance, strategy and capital allocation. The following summarizes the principal holders, their stakes and the likely effects on corporate direction.
| Investor | Ownership (%) | Position / Role | Immediate Impact |
|---|---|---|---|
| Shouchen Zhu | 38.0% | Controlling shareholder | Decisive voting control; ability to set board composition and long-term strategy |
| Jifen Huang | 3.6% | Member of the Board of Directors (3rd largest shareholder) | Active governance involvement; direct influence on operational oversight |
| Xuewei Chen | 1.2% | CEO | Personal alignment with shareholder value and operational execution |
| Top insiders (combined) | 42.8% | Controlling block | Concentrated decision-making, potential for unified long-term strategy |
| Institutional investors | Limited presence | External owners | Lower external monitoring; more managerial flexibility |
- Control dynamics: With a 38% stake, Shouchen Zhu can effectively steer major corporate actions (M&A, dividend policy, capital structure) without needing a majority coalition.
- Board influence: Jifen Huang's dual status as a 3.6% owner and board member signals active insider governance rather than passive shareholding.
- Management alignment: CEO Xuewei Chen's 1.2% holding provides a measurable personal incentive to execute strategy that supports mid-to-long-term share performance.
- Strategic implications: High insider ownership typically favors long-horizon investments (capex, R&D, vertical integration) over short-term earnings smoothing.
- Operational efficiency: Concentrated ownership can produce quicker decision cycles and coherent strategic execution, reducing agency frictions common in broadly held firms.
- Governance trade-offs: Limited institutional pressure reduces external oversight and activist checks, increasing reliance on the controlling shareholders' stewardship quality.
Key numerical snapshot of ownership concentration:
| Category | Aggregate % |
|---|---|
| Controlling shareholder (Shouchen Zhu) | 38.0 |
| Top named insiders (Zhu + Huang + Chen) | 42.8 |
| Remaining public float / institutions | ~57.2 |
For additional context on the company's financials and metrics that interplay with investor behavior, see: Breaking Down Hebei Jianxin Chemical Co., Ltd. Financial Health: Key Insights for Investors
Hebei Jianxin Chemical Co., Ltd. (300107.SZ) - Market Impact and Investor Sentiment
Hebei Jianxin Chemical Co., Ltd. (300107.SZ) has drawn renewed market attention driven by a combination of favorable market valuation metrics and underlying operational headwinds. As of February 16, 2025, the company's market capitalization reached approximately CNY 5.6 billion, following a 7.1% stock price gain leading up to that valuation. The low beta of 0.505 signals lower volatility versus the broader market, which has shaped investor positioning.- Market cap (16 Feb 2025): CNY 5.6 billion
- Recent price movement: +7.1% into valuation date
- Beta: 0.505 (low volatility profile)
- Revenue trend: -25.35% YoY (TTM ending 30 Jun 2025)
| Metric | Value | Implication |
|---|---|---|
| Market Capitalization | CNY 5.6 billion (16 Feb 2025) | Perceived market value; supports liquidity and institutional interest |
| Stock Price Change | +7.1% (leading up to valuation) | Short-term investor confidence / momentum |
| Beta | 0.505 | Lower volatility; attractive to conservative portfolios |
| Revenue (TTM) | -25.35% YoY (ending 30 Jun 2025) | Significant decline; raises growth and margin concerns |
| Sector Focus | Specialty chemical products; international markets | Differentiation potential; exposure to cross-border demand |
- Drivers attracting buyers:
- Low volatility (beta ~0.505) for conservative allocations
- Recent positive price momentum (+7.1%) signaling renewed interest
- Sector niche in specialty chemicals and export exposure
- Deterrents tempering enthusiasm:
- Material revenue contraction: -25.35% YoY (TTM ending 30 Jun 2025)
- Potential margin pressure and uncertainty about near-term recovery
Hebei Jianxin Chemical Co., Ltd. (300107.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.